SarahChen_PharmD said:Steady state is faster than people expect: half-life about five days, so you are at plateau in roughly three to four weeks rather than five.
I read this differently from SarahChen_PharmD, on substance rather than tone. The "tirzepatide is simply better" summary irritates me. It is better on mean weight loss, and the cardiovascular outcome evidence is far thinner than semaglutide's. If the reason for treating is cardiovascular risk rather than weight, the evidence base points the other way.
One concrete data point for the thread. One practical note: write down what you did and when, before you need it. Reconstructing a timeline from memory three months later is how people end up unable to answer the one question that would have resolved it.
JennaRN said:The "tirzepatide is simply better" summary irritates me.
Adding the part of the answer the thread has not reached. Most of what circulates confidently in this community traces back to one summary of one study, and the qualifier was dropped somewhere in the third retelling.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsFollowing on from PeptideChemSF — and this may be the naive question:
How much of the tirzepatide advantage is the GIP component and how much is simply that the dose ladder goes higher in receptor-occupancy terms?
Closing the loop on my own question.
Update: the eight-week restart pattern people described is exactly what happened. I nearly abandoned it at week five.